New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, AIDS, and solid tumors

Shen, Rongkun; Lü, Li; Broxmeyer, Hal E.

doi:10.1016/1040-8428(90)90034-p

Cited by 12 publications

(4 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCID mice have been used extensively to study human leukemia and other malignancies, and for modeling human retroviral pathogenesis including anti-viral gene therapy. [15][16][17][18][19][20] Thus, SCID mice appeared also to be ideal candidates to initiate experiments to get first insights into the feasibility of cell type-specific gene transfer in vivo. Moreover, reticuloendotheliosis viruses (REV) are not infectious and/or pathogenic in man or rodents.…”

Section: Resultsmentioning

confidence: 99%

In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies

Jiang

Dornburg

1999

Gene Ther

View full text Add to dashboard Cite

Cell type-specific gene delivery will be essential for in vivo display scAs against the human her2neu cell surface progene therapy. Our laboratory has previously developed tein, was injected. Cells were recovered from the peritoretroviral vector particles, derived from spleen necrosis neum, subjected to antibiotic selection, and tested for the virus, SNV, which display the antigen-binding site of an expression of a lacZ gene transduced by the retroviral vecantibody on the viral surface. Such particles infected only tor. We found that human target cells, which express her2-human cells in vitro, which expressed a receptor recogneu, were infected in vivo. However, neither human cells nized by the antibody. To test cell type-specific gene delivthat do not express her2neu, nor normal mouse cells were ery in vivo, a mouse model system has been developed.infected by such viral particles. These data give proof of Antibiotic resistant human target and non-target cells were principle that retroviral vector-mediated, cell type-specific injected into the peritoneum of SCID mice. Subsequently, gene delivery can be obtained in vivo. a vector solution containing 10 6 infectious particles, which

show abstract

Section: Resultsmentioning

confidence: 99%

In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies

Jiang

Dornburg

1999

Gene Ther

View full text Add to dashboard Cite

show abstract

“…Cytokines are currently being evaluated as immunomodulatory and therapeutic agents in the clinic (Gillis et al, 1986;Broxmeyer and Vadhan-Raj, 1989). To this end they have been assessed for possible anti-tumor effects in animal tumor models (Shen et al, 1990). One cytokine that may be of use is the macrophage colony-stimulating factor (M-CSF or CSF-I), a glycoprotein required for the growth and differentiation of macrophage progenitors as well as the survival of mature macrophages (Das et al, 1982;Ralph et al, 1989;Broxmeyer et al, 1990).…”

mentioning

confidence: 99%

Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells

Lü

Shen

Lin

et al. 1991

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was evaluated for efficacy, either alone or in combination with local X-irradiation (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) cells. The size of the primary tumor and numbers of lung metastases, 21 days after tumor inoculation and 15 days after the start of treatment, were reduced by 87% in tumor-bearing mice treated with 20 micrograms/dose M-CSF s.c. twice a day for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate anti-tumor effect and enhanced the anti-tumor effect of M-CSF. Hematological parameters, including nucleated cellularity in peripheral blood, femoral marrow, spleen and peritoneal exudate, as well as marrow and splenic granulocyte-macrophage progenitor cells, and numbers of splenic Thy 1.2+ cell and peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either agent alone, was associated with a significant, although slight, enhancement in survival time for LLC-bearing mice. Inability to obtain a better survival-enhancing effect appeared to be related to the limited treatment, since the anti-tumor effects of M-CSF were more notable early on in disease progression and were related to the dose of M-CSF used. The effects of M-CSF were most probably indirect ones on the host immune system. M-CSF, in combination with LR, may be of benefit in the treatment of human tumors that have metastatic potential.

show abstract

“…The LLC cell line was maintained as a transplantable strain in mice and was provided by the cell depository of the Institute of Cytology and Genetics SB RAS (Novosibirsk, Russia). LLC is widely used as a model of lung cancer, and exhibits high tumorigenicity and metastasis to the lungs in C57BL mice [43][44][45][46]. Subcutaneous transplantation leads to the development of a primary node at the injection site and the appearance of metastases in the lungs on days 17-21 [47].…”

Section: Sensitizing Properties Of Usnic Acid Derivatives In Vitromentioning

confidence: 99%

Enhancement of the Antitumor and Antimetastatic Effect of Topotecan and Normalization of Blood Counts in Mice with Lewis Carcinoma by Tdp1 Inhibitors—New Usnic Acid Derivatives

Kornienko,

Chepanova,

Zakharenko

et al. 2024

IJMS

View full text Add to dashboard Cite

Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme and one of the causes of tumor resistance to topoisomerase 1 inhibitors such as topotecan. Inhibitors of this Tdp1 in combination with topotecan may improve the effectiveness of therapy. In this work, we synthesized usnic acid derivatives, which are hybrids of its known derivatives: tumor sensitizers to topotecan. New compounds inhibit Tdp1 in the micromolar and submicromolar concentration range; some of them enhance the effect of topotecan on the metabolic activity of cells of various lines according to the MTT test. One of the new compounds (compound 7) not only sensitizes Krebs-2 and Lewis carcinomas of mice to the action of topotecan, but also normalizes the state of the peripheral blood of mice, which is disturbed in the presence of a tumor. Thus, the synthesized substances may be the prototype of a new class of additional therapy for cancer.

show abstract

New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, AIDS, and solid tumors

Cited by 12 publications

References 105 publications

In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies

In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies

Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells

Enhancement of the Antitumor and Antimetastatic Effect of Topotecan and Normalization of Blood Counts in Mice with Lewis Carcinoma by Tdp1 Inhibitors—New Usnic Acid Derivatives

Contact Info

Product

Resources

About